News 2021
OBI Pharma Announces Phase 2 Studies Patient Enrollment for OBI-999 and OBI-3424
SOLID TUMOR PATIENTS WITH HIGH GLOBO H OR AKR1C3 EXPRESSION WILL BE ENROLLED. TAIPEI, Taiwan, January 24, 2022 — OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced that …
OBI Pharma Announces First Cancer Patient Enrolled on OBI-999 in Phase 2 Study
OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced that the first patient has been enrolled on the Phase 2 study of OBI-999. OBI-999 is a novel antibody drug …
OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network’s OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL
First clinical trial to evaluate the safety and efficacy of OBI-3424, a DNA alkylating agent targeting AKR1C3 enzyme, in T-Cell Acute Lymphocytic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) TAIPEI, Taiwan, …
Poster Presentation at AACR 2021 Annual Meeting for OBI-3424, OBI-998, GLOBO H and SSEA-4
Title: Selective and Broad Anti-tumor Activity of AKR1C3-activated Prodrug AST-3424/OBI-3424 Poster Number: 1220 / Abstract number: 1062 Title: Preclinical characterization of a novel SSEA4-targeting antibody drug conjugate, OBI-998 Poster number: …
OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4
Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 small molecule pro-drug), OBI-998 (SSEA-4 ADC) and the glycosphingolipid cancer antigens, Globo H and SSEA-4. Taipei, Taiwan. April 06, 2021 …
OBI Pharma, Inc. to Present at the 39th J.P. Morgan Healthcare Conference
Taipei, Taiwan. January 6, 2021 — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that Tillman Pearce, MD., Chief Medical Officer, will present a company and clinical development …